Breaks Categories: News

TuesdayMay 18, 2021 1:15 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Secures IRB Approval to Commence Study of Psilocybin Formulation in Treatment of Major Depressive Disorder

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that the Institutional Review Board ("IRB") at the University of the West Indies Hospital in Jamaica has granted approval to commence the study of its sublingual psilocybin formulation ("CYB001") in a Phase II clinical trial for patients suffering with major depressive disorder ("MDD"). Commencement of the trial is subject to final confirmation of study material specifications by Jamaica’s Ministry of Health. "IRB approval for our study protocols is an important step forward to begin testing our proprietary psilocybin formulation delivered via absorption under the tongue…

Continue Reading

FridayMay 14, 2021 9:56 am

PsychedelicNewsBreaks – WWC Conference Celebrates Women in Cannabis, Psychedelic Industries

The second-annual Womxn, Wellness and Cannabis Conference (“WWC Conference”) is expected to be the largest virtual event for women in the cannabis and psychedelic industries. Slated for May 26–27, the two-day event is hosted by Marigold PR in association with Lift & Co. Expo, a platinum partner and North America’s largest cannabis industry conference and tradeshow. The largest free event of its kind, the conference unites women globally for two days and features women-led panel discussions, Q&As and keynote speakers. The first day of the conference will focus on cannabis; the second day will focus on psychedelics. The conference agenda…

Continue Reading

FridayMay 14, 2021 9:38 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Six Keys to Leadership Growth in “Forbes” Article

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was featured in a recent “Forbes” article touting six keys to leadership growth. In the article, McKee shared valuable insight into the most effective ways that leaders can grow and develop. The behaviors McKee encouraged include staying curious and stepping outside of your comfort zone as well as not waiting for experiences and making experiences as you go. McKee also urged potential leaders to never stop learning and, in fact, noted that they could learn from every experience. McKee also encouraged leaders to not be afraid of breaking with convention.…

Continue Reading

WednesdayMay 12, 2021 11:47 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Opens Functional Mushroom Direct-to-Consumer Store on Amazon

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, has opened an online, direct-to-consumer, e-commerce store through its wholly owned subsidiary, Pure Mushrooms Corp. The store, which will sell Pure Mushrooms Reishi and Maitake product formulations, is on the Amazon platform. Pure Mushroom Reishi and Maitake formulations are available in convenient, gluten-free capsules; the company anticipates releasing  a Lion’s Man formulation this summer. “We are excited to be on Amazon, the largest online marketplace and the most powerful platform in the world for brand…

Continue Reading

TuesdayMay 11, 2021 9:44 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) CEO Talks Business in Two Video Interviews

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) director and CEO Hugh Rogers was a featured guest on two different video interviews. In both interviews, Rogers shared key information and updates about XPhyto, a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. During his InvestorIntel interview with host Peter Clausi, Rogers mentioned that the company had recently received European approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system called Covid-ID Lab, which is now registered within the European Union as a commercial in vitro diagnostic (“CE-IVD”) test. During the interview, Rogers noted that the…

Continue Reading

FridayMay 07, 2021 11:03 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Launches ‘Covid-ID Lab’ POC Pilot Project in Germany

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced its commencement of a pilot project with its rapid COVID-19 PCR test ("Covid-ID Lab") in a point-of-care ("POC") setting in Germany. Covid-ID Lab was recently approved in Europe and offers the accuracy of a PCR test in only 25 minutes. Validated work flows, including mobile collection and processing of patient samples, will be further optimized during the test. XPhyto's clinical partner for the project is Spitzweg Apotheke, a well-known pharmacy in Langen near Frankfurt, Germany, currently running a COVID-19 test center at a clinic, where it also provides special pharmacy…

Continue Reading

FridayMay 07, 2021 9:28 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) CEO to Present at Global Small Cap Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced that CEO Doug Drysdale will be presenting at the upcoming Benzinga Global Small Cap Conference. The conference, slated for Thursday, May 13, 2021, is designed to connect promising small cap companies with investors and traders. Drysdale’s presentation on Cybin is scheduled to begin at 3:55 p.m. ET. The presentation will be broadcast live; a replay will also be available for seven days following the conference. In addition to his Cybin presentation, Drysdale will also serve as a key member of a panel discussion focused on investing…

Continue Reading

ThursdayMay 06, 2021 1:00 pm

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured on Gamechangers LIVE

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) was featured in a recent episode of Gamechangers LIVE, a podcast series that shines a spotlight on individuals who are gamechangers in their fields and shares perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. XPhyto Therapeutics’ CEO and Director, Hugh Rogers, joined the broadcast, hosted by Executive Coach and Speaker Sergio Tigera, to discuss the company’s various lines of business, including its work to scale industrial production of pharmaceutical-grade psychedelics. “The psychedelic space is really exciting. This is absolutely the cutting edge of mental…

Continue Reading

MondayMay 03, 2021 11:07 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Releases Corporate Update

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, has provided a corporate update regarding its cannabis, functional mushroom and psilocybin business operations. The update notes that, in spite of COVID-19, its Pemberton, British Columbia facility is fully operational and in daily production. The company is focused on scalable entry into the U.S. market through a partnership with an Oregon-based, multistate operator (“MSO”). The company intends to produce its own branded products as well as white label products. In Canada, the company is ramping…

Continue Reading

MondayMay 03, 2021 10:13 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) Announces Partnership with Leading Educational Platform to Provide Psychedelic Therapy Training

Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, has entered a master service agreement with Fluence, an expertise-driven educational platform that provides professional training in psychedelic therapy and psychedelic integration for psychiatrists, psychotherapists, social workers, and other healthcare practitioners. The partnership will provide design and training for the psychotherapeutic component of Tryp's clinical trial activities and will strengthen Tryp's capability to plan and implement clinical trials. The agreement will also enhance the company’s ability to make the most of the information gathered. Fluence has specific expertise in psychedelic clinical trials…

Continue Reading